According to CNBC, a report by a Goldman Sachs analysts notes that gene therapy treatment could be "bad for business in the long run."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
|“Inhibiting this pathway has extended life span in every species studies to date.”|
|“What if aging didn’t have to suck?”|
|We're All Going to Die!!! #OilSPill|
|The End of Antibiotics, Period|
|“Both spacecraft are still operational when they reached interstellar space.”|
|"Free apps make money by selling your personal data."|
|CaptchaTweet: Write Tweets in Captcha Form|
|How to Avoid Jury Duty|
|The (Very Scary) People of Public Transit|
|“Initial riders may be more comfortable getting into a car with a human in the driver seat.”|
|Naked Preacher Lady [NSFW]|
|Fake Name Generator|
|The Festive Funk Machine: Click to Make Your Own Festive Music|
|Recycled Vacuum Lamps|